Pulmonary therapy for cystic fibrosis. pp. 25-37.

This report summarizes selected aspects of pulmonary therapy for cystic fibrosis. Since 
the results of chronic bronchopulmonary infection are the cause of death 
in most CF patients, improved patient survival patterns may possibly be 
attributed in large part to improvements in antibiotic therapy and increased 
therapeutic aggressiveness. Mist tent therapy was defined and initiated in the 
1950s, but later studies of mist tent therapy have not shown 
beneficial response in many patients selected for study. Intermittent aerosol therapy 
continues to be employed by many physicians to deliver medication rather 
than bulk liquid to the bronchial mucosa. Pulmonary endoscopy and lavage, 
expectorants, allergic aspergillosis, pneumothorax, lobectomy, and hemoptysis are also examined. 